Literature DB >> 3891922

The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia.

S L George, J J Ochs, A M Mauer, J V Simone.   

Abstract

We assessed the influence of an initial isolated meningeal relapse on treatment outcome in 839 children with acute lymphoblastic leukemia (ALL) who were admitted to St Jude Children's Research Hospital (Memphis) from mid-1967 through mid-1979. The patients were entered in a series of five clinical trials (Total Therapy Studies V through IX), each designed to test one or more modifications of treatment for ALL. Two groups were compared: 699 children who received CNS prophylaxis (2,400-rad craniospinal irradiation or 2,400-rad cranial irradiation plus intrathecal methotrexate) v 56 who did not. Our results, obtained with a time-dependent covariate model and a matching technique, indicate a 2 to 3.5-fold increase in the risk of hematologic relapse or death among patients who experienced an isolated CNS relapse compared with similar patients (matched for leukocyte count and length of complete remission) who remained free of CNS involvement. Of the 107 children with an initial isolated CNS relapse, 89 (83%) have died or have had a subsequent relapse. There was no detectable difference in the rate of hematologic relapse or death after a CNS relapse between patients who had received preventive therapy and those who had not. We conclude that CNS prophylaxis is important both for the prevention of initial CNS leukemia and for reducing the risk of hematologic relapse or death subsequent to a CNS relapse.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891922     DOI: 10.1200/JCO.1985.3.6.776

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.

Authors:  Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Sherry Pierce; Jianquin Shan; Jorge Cortes; Susan O'Brien
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

2.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

3.  Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups.

Authors:  Masahito Tsurusawa; Keiko Yumura-Yagi; Akira Ohara; Junichi Hara; Naoyuki Katano; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 4.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy.

Authors:  Susan O'Brien; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Jorge Cortes; Gautum Borthakur; Sherry Pierce; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

6.  CNS minimal disease therapy in childhood leukaemia: the place for irradiation.

Authors:  O B Eden
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

7.  Prognostic factors for clinical outcomes of patients with central nervous system leukemia.

Authors:  Jinai Bharucha; Qing Cao; Zohar Sachs; Angela Smith; Sarah Williams; Khalid Amin; Veronika Bachanova; Erica Warlick; Claudio Brunstein; Daniel Weisdorf; Nelli Bejanyan
Journal:  Hematol Oncol Stem Cell Ther       Date:  2020-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.